Triumvira
We leverage a T cell’s recognition, activation, and signaling properties.
Triumvira’s proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.
For more information, please view our Corporate Presentation linked below.
Triumvira Corporate Presentation – 2mb PDF
